2024-09-10
Проводит National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Страница компанииULTRAsound-assisted Catheter-guided Thrombolysis for Intermediate-high Risk Patients With Pulmonary Embolism
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT07452991/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование идёт, в реестре указано, что набор участников открыт.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 300 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановое окончание — 09.2030.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 11 · невключение: 16
Критерии включения
- Adults aged ≥ 18 years at time of enrollment;
- Ability to provide written informed consent (or legally authorized representative consent where applicable);
- Objectively confirmed acute pulmonary embolism (PE) by contrast-enhanced computed tomography pulmonary angiography (CTPA) demonstrating intraluminal filling defects in at least one segmental, lobar, or more proximal pulmonary artery;
- Hemodynamically stable at presentation (i.e., not meeting high-risk PE criteria of sustained hypotension, shock, or need for vasopressor support per ESC 2019 and AHA/ACC risk stratification);
- Evidence of right ventricular (RV) dysfunction on imaging (e.g., RV/LV ratio > 1.0 on CTPA or echocardiography);
- Elevated cardiac biomarkers, including troponin I or T above the upper limit of normal;
- Intermediate-high risk features defined as the combination of imaging RV dysfunction and positive cardiac biomarkers, consistent with ESC stratification;
- At least one clinical indicator of elevated early risk such as:
- Tachycardia (e.g., HR ≥ 100 bpm),
- Mild systolic blood pressure reduction (e.g., SBP ≤ 110 mmHg but not meeting high-risk thresholds),
- Hypoxemia (SpO₂ < 90% on room air).
Критерии невключения
- Presence of hemodynamic instability, defined as at least one of the following:
- Systolic blood pressure (SBP) < 90 mmHg or a drop ≥ 40 mmHg from baseline for > 15 minutes not attributable to arrhythmia, hypovolemia, or sepsis,
- Requirement for vasopressors to maintain SBP ≥ 90 mmHg,
- Cardiogenic shock, defined by clinical signs of end-organ hypoperfusion (e.g., altered mental status, oliguria, lactate elevation),
- Need for ECMO or other mechanical circulatory support initiated prior to assessment,
- Cardiac arrest requiring resuscitation.
- Active major bleeding or conditions with high bleeding risk (e.g., known intracranial pathology predisposed to hemorrhage or associated with ongoing pharmacotherapy);
- Recent (< 3 months) intracranial or intraspinal surgery, major trauma, or stroke;
- Known central nervous system neoplasm or metastatic cancer with high bleed risk.
- Administration of systemic thrombolytic agents or catheter-directed thrombolysis prior to registry assessment for the index PE episode;
- Known hypersensitivity to alteplase, unfractionated heparin (UFH), or any of their excipients.
- Requirement for intensive care admission for conditions unrelated to the index PE;
- Duration of symptoms attributable to the index PE > 14 days at presentation, as defined in contemporary trial criteria;
- Known severe thrombocytopenia (e.g., platelet count < 100 × 10⁹/L) or coagulopathy precluding safe catheter access;
- Life expectancy < 6 months due to advanced comorbid disease unrelated to acute PE;
- Pregnancy.
Источник: ClinicalTrials.gov, NCT07452991 · запись обновлена в реестре 17 марта 2026.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 16
- All-cause mortality — 48 hours post-procedure. At day 7 after procedure or at discharge, if earlier. At day 360 of follow-up.
- Net Adverse Clinical Events (NACE) — 48 hours post-procedure. At day 7 after procedure or at discharge, if earlier. At day 360 of follow-up.
Цель исследования
Pulmonary embolism (PE) is a life-threatening condition and a leading cause of cardiovascular mortality. While systemic thrombolysis is the standard treatment for high-risk PE, its bleeding risk limits use in some patients, highlighting the need for alternative reperfusion strategies such as catheter-directed thrombolysis (CDT). This prospective study will evaluate the safety and efficacy of CDT using the EkoSonic Endovascular System (EKOS; Boston Scientific) in patients with intermediate-high and high-risk PE. The primary outcome is all-cause mortality through 360 days of follow-up, with secondary outcomes including changes in echocardiographic parameters such as the RV/LV diameter ratio.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT07452991 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, набор участников, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.